Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Pharmacovigilance

The legacy of general health and science information dissemination has long served as a foundation for public understanding of medical conditions and treatments. Within this tradition, comprehensive health resources have provided communities with accessible knowledge about disease prevention, treatment options, and medication management. This broad educational framework has historically emphasized the importance of informed patient-provider communication and awareness of potential treatment-related outcomes. Transitioning from this general health context, a focused examination of specific medication exposures and their associated risks becomes necessary. In particular, the relationship between bisphosphonate therapy, such as Fosamax, and the development of osteonecrosis of the jaw represents a critical area of clinical concern. This condition, characterized by exposed necrotic bone in the maxillofacial region, has been documented in patients receiving these medications for osteoporosis and other bone disorders. The clinical evidence review of Fosamax and osteonecrosis of the jaw causation requires careful consideration of exposure duration, dosage, and patient-specific risk factors. This pivot from general health education to a targeted occupational and clinical exposure concern underscores the need for precise risk communication. Healthcare providers and patients alike benefit from understanding the temporal relationship between medication initiation and potential adverse outcomes, without overstating mechanistic certainty. This transition maintains the neutral academic tone essential for evidence-based discourse while narrowing focus from broad health literacy to specific pharmacovigilance considerations.

Fosamax: Indications and Mechanism of Action

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on identifying necrotic bone that persists for more than eight weeks. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and remodeling. In the jawbone, which undergoes high rates of remodeling due to daily mechanical stress and dental procedures, this suppression can lead to microdamage accumulation and impaired healing. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jawbone that may predispose it to ONJ under bisphosphonate therapy. The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This suggests that both short-term and long-term users can be affected, but cumulative exposure heightens risk. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions." It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials was low and not statistically different from placebo, which may complicate risk communication. For affected patients, causation considerations are complex. ONJ can occur spontaneously, and its association with bisphosphonates is based on epidemiological evidence and case reports rather than randomized controlled trials. The label acknowledges that ONJ is generally associated with tooth extraction and/or local infection, but it also states that it has been reported in patients taking bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This implies that while Fosamax is a contributing factor, other local and systemic factors play a role. The risk may be higher in patients with cancer receiving high-dose bisphosphonates, but Fosamax is primarily used for osteoporosis at lower doses. Nonetheless, the label does not differentiate by dose or indication, so all users are considered at potential risk.

Summary of Clinical Evidence

In summary, the clinical evidence supports a causal link between Fosamax and osteonecrosis of the jaw, with mechanistic plausibility and a variable timeline from exposure to harm. Warnings in the prescribing information are present but may be limited by the low incidence in clinical trials. Patients and healthcare providers should weigh the benefits of fracture reduction against the risk of ONJ, especially in those with additional risk factors such as dental procedures or prolonged use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on identifying necrotic bone that persists for more than eight weeks. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.